香雪製藥(300147.SZ)擬轉讓九極生物100%股權予廣州淡水泉
格隆匯12月31日丨香雪製藥(300147.SZ)公佈，為進一步聚焦主營業務的發展，整合優化資產結構及資源配置，提高資產流動性及使用效率，增強核心競爭力，公司擬將部分資產剝離後的廣東九極生物科技有限公司(“九極生物”、“目標公司”)100%股權轉讓給廣州淡水泉資產管理有限公司(“廣州淡水泉”)。為此，公司與廣州淡水泉簽署了《廣州市香雪製藥股份有限公司與廣州淡水泉資產管理有限公司關於轉讓廣東九極生物科技有限公司之股權轉讓協議》，公司擬通過股權轉讓的方式將部分資產剝離後的九極生物100%股權(“交易標的”)以9000萬元轉讓給廣州淡水泉。
此次交易的範圍包括：(1)此次交易的範圍為目標公司的100%股權，包括目標公司現有的業務、直銷員或經銷商資源、品牌、商標、專利、專有技術、食品生產許可證、食品經營許可證、直銷經營許可證、保健食品註冊批件、直銷電子交易系統。(2)目標公司目前擁有的9個直銷區域、10個分公司及30個直銷服務網點。(3)經營性資產及負債，包括目標公司截至交割日的經營性資產及負債，其中包括目標公司現有存貨、應付獎金、加工費、現有已租的辦公樓及倉庫(定金和剩餘預繳的管理費由廣州淡水泉承擔，已繳納部分由廣州淡水泉退回公司)，具體經營性資產及負債雙方以附件形式詳細約定。
此次交易完成後，九極生物將不再納入公司合併報表範圍核算，經公司財務部門初步測算，預計整體影響合併報表 2019年淨利潤金額增加約240萬元，不會對公司財務狀況和經營成果產生重大影響，此次交易的具體收益以2019年度審計報告中披露的數據為準。
公司根據業務發展規劃和實際經營需要轉讓九極生物的股權，整合優化了資產結構及資源配置，提高了資產流動性及使用效率，有利於公司聚焦主營業務的發展，增強核心競爭力，同時也進一步完善了公司的管理體系與股權架構，降低了經營及管理成本，為公司帶來了正向的流動資金和合作收益，符合公司整體戰略發展規劃。此次股權轉讓獲得的資金將用於補充公司流動資金，有利於改善公司現金流，符合公司實際經營和未來發展需要，不存在損害上市公司和股東、特別是中小股東利益的情形。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
